Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas on May 16, 2024.

Dr. Chunxia Lily Zhao, Director of Antibody Discovery at Astria Therapeutics, will present a poster titled, "Preclinical Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody" at Session One of the Pharmacology and Therapeutic Development Select E-Poster Discussions on May 16, 2024, at 5:00pm CDT.

About Astria Therapeutics :

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics Inc.

Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
FPX Nickel Signs Exploration Agreement with Takla Nation for Klow Property

FPX Nickel Signs Exploration Agreement with Takla Nation for Klow Property

 FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) (" FPX " or the " Company ") is pleased to announce the signing of an Exploration Agreement (the " Agreement ") with the Takla Nation for exploration activities associated with the Klow property in central British Columbia . The Agreement outlines a collaborative framework for FPX and Takla Nation to move forward responsibly with early-stage exploration, establishing important protocols for engagement, environmental protection, employment, training, and business opportunities.

"This Agreement underscores our commitment to engagement with Indigenous communities from the earliest stages of our exploration work," said Martin Turenne , President, CEO, and Director of FPX. "We look forward to continuing to work with the Takla Nation, guided by transparency, respect, and a shared vision for sustainable development in Takla territory."

"The signing of this agreement marks an important step in strengthening our relationship with FPX. By establishing clear principles for engagement, this agreement ensures that our voices are heard from the earliest stages of exploration," commented Chief John French of Takla Nation. "We look forward to working collaboratively with FPX to protect our lands and ensure shared benefits for our community."

Background

The Klow Property is situated approximately 120 km northwest of Fort St. James and around 45 km north of FPX's flagship Baptiste Nickel Project. Portions of the Klow Property are accessible via an all-season public road which connects Fort St. James to Takla Landing . Like the Baptiste Nickel Project, the exploration target for the Klow property is nickel in the form of awaruite, a sulphur-free, nickel-iron mineral (Ni 3 Fe) hosted by serpentinized ultramafic rocks.

Exploration at the Klow Property has advanced in several stages since its initial evaluation. Between 2010 and 2012, FPX conducted geological mapping and rock sampling that delineated a large awaruite target area measuring approximately 1.5 by 1.0 kilometres, with encouraging surface grades. In 2012, a five-hole, 1,579-metre diamond drill program tested a portion of this target, with hole DH-4 intersecting 316 metres grading 0.10% nickel-in-alloy 1 from 10 metres downhole. In 2024, the Company re-analyzed 68 archived core samples from DH-4 using Davis Tube Recoverable (DTR) methods, which confirmed strong correlation with historical nickel-in-alloy values and returned DTR nickel grades averaging 7–10% higher than the original nickel-in-alloy results. Also in 2024, FPX expanded the Klow mineral claims to 251 km 2 , covering mainly prospective ultramafic rocks of the Trembleur Ultramafite, host to mineralization at Baptiste.

As announced in May 2025 , FPX undertook a summer 2025 surface rock sampling program, 100% funded by the Japan Organization for Metals and Energy Security (" JOGMEC "). The Agreement with Takla Nation will enable planning and readiness for future exploration activities.

Klow Property Earn-In Agreement

As previously disclosed, FPX and JOGMEC have entered into an earn-in agreement (the " Klow Earn-In Agreement ") which provides JOGMEC the option to earn a beneficial interest in the Company's Klow Property in central British Columbia .

The key terms of the Klow Earn-in Agreement are as follows:

  • FPX grants to JOGMEC the option to earn a 60% beneficial interest in Klow by funding $1,000,000 in exploration expenditures by no later than March 31, 2027 (extended from a prior deadline of March 31, 2026 by mutual agreement of the parties)
  • Once JOGMEC has earned its 60% beneficial interest in Klow, the parties will thereafter fund exploration expenditures pro rata to their ownership interest
  • If either party's beneficial interest in Klow is diluted below 10%, that party's beneficial interest will be converted into a 1.5% NSR royalty over Klow, with the other party retaining a right to buy-back 1.0% of the NSR royalty for $3,500,000

Note 1: results were obtained by geochemical analysis and may not accurately represent Davis Tube Recoverable (DTR) nickel grades. DTR nickel values refer to the portion of the total contained nickel that is recovered from a magnetically separated fraction of the sample. Nickel-in-alloy results refer to nickel recovered by a selective geochemical leach which targets nickel contained in awaruite. While both methods measure nickel in awaruite, awaruite particle exposure and grain size influence each method slightly differently, therefore these results are not directly comparable.

Keith Patterson , P.Geo., FPX's Vice President, Exploration, FPX's Qualified Person under NI 43-101, has reviewed and approved the scientific and technical content of this news release.

About FPX Nickel Corp.

FPX Nickel Corp. is focused on the exploration and development of the Baptiste Nickel Project, located in central British Columbia , and other occurrences of the same unique style of naturally occurring nickel-iron alloy mineralization known as awaruite. For more information, please view the Company's website at https://fpxnickel.com/

On behalf of FPX Nickel Corp.

"Martin Turenne"

Martin Turenne , President, CEO and Director

Forward-Looking Statements

Certain of the statements made and information contained herein is considered "forward-looking information" within the meaning of applicable Canadian securities laws. These statements address future events and conditions and so involve inherent risks and uncertainties, as disclosed in the Company's periodic filings with Canadian securities regulators. Actual results could differ from those currently projected. The Company does not assume the obligation to update any forward-looking statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE FPX Nickel Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2025/01/c9322.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Silver47 Completes Successful Red Mountain Drill Program and Intersects Massive Sulfides in Multiple Holes

Silver47 Completes Successful Red Mountain Drill Program and Intersects Massive Sulfides in Multiple Holes

The Red Mountain Deposit Remains Open to Expansion in Multiple Directions with Assays Pending

Silver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) ("Silver47" or the "Company") is pleased to announce the completion of its summer 2025 drill program at its wholly-owned Red Mountain Project in south-central Alaska.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Redstone Completes Strongly Supported Placement

Redstone Completes Strongly Supported Placement

Redstone Resources Limited (ASX Code: RDS) (‘Redstone’ or the ‘Company’) is pleased to advise that it has received binding commitments for a private placement to professional and sophisticated investors of up to A$650,000 (before costs), exceeding the minimum raising target of $500,000. The terms of the share placement comprise the issue of 185,714,286 million fully paid ordinary shares in the Company at an issue price of 0.35 cents per share (Placement Shares) and, subject to shareholder approval, placement participants will also receive a one (1) for three (3) free attaching unlisted $0.007 option exercisable for a period of one (1) year from the date of issue (Placement Options), (the Placement).

The Placement provides funding to continue its planned work programs to unlock the potential of its 100% owned West Musgrave Copper project (the ‘Project’) in Western Australia.

Keep reading...Show less
Vertex Minerals Limited  2025 Annual Report

Vertex Minerals Limited 2025 Annual Report

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) (OTCMKTS:VTXXF) holds a portfolio of high-grade gold projects in New South Wales and Western Australia, anchored by the flagship Hill End Gold Project. Together with the nearby Hargraves Gold Project, located 35 kilometres to the north, these assets form a district-scale position within the highly prospective Hill End - Hargraves corridor, which has historically produced more than four million ounces of gold.

The Company's priority during the year ended 30 June 2025 was advancing Hill End from development into production. This work culminated in the achievement of first gold in August 2025, marking Vertex's successful transition from explorer to producer. Hargraves provides additional exploration potential and the opportunity to establish a long-term satellite ore source, complementing production at Hill End and supporting the Company's vision of building a sustainable gold hub in the district.

*To view the Annual Report, please visit:
https://abnnewswire.net/lnk/X78F5UJ7



About Vertex Minerals Limited:

Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Angkor's Energy Subsidiary Completes 2d Seismic Program On Block VIII Cambodia

Angkor's Energy Subsidiary Completes 2d Seismic Program On Block VIII Cambodia

(TheNewswire)

GRANDE PRAIRIE, AB, (September 30, 2025): - TheNewswire - Angkor Resources Corp. (TSXV: ANK and OTC: ANKOF) ("Angkor" or "the Company") announces its energy subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") has completed the onshore 350-line kilometer 2D seismic program on Block VIII, including the newly added area of Mussel Basin.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News